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Abstract Poly(ADP-ribosyl)ation is a ubiquitous protein
modiﬁcation found in mammalian cells that modulates
many cellular responses, including DNA repair. The
poly(ADP-ribose) polymerase (PARP) family catalyze the
formation and addition onto proteins of negatively charged
ADP-ribose polymers synthesized from NAD
?. The
absence of PARP-1 and PARP-2, both of which are acti-
vated by DNA damage, results in hypersensitivity to
ionizing radiation and alkylating agents. PARP inhibitors
that compete with NAD
? at the enzyme’s activity site are
effective chemo- and radiopotentiation agents and, in
BRCA-deﬁcient tumors, can be used as single-agent ther-
apies acting through the principle of synthetic lethality.
Through extensive drug-development programs, third-
generation inhibitors have now entered clinical trials and
are showing great promise. However, both PARP-1 and
PARP-2 are not only involved in DNA repair but also
in transcription regulation, chromatin modiﬁcation, and
cellular homeostasis. The impact on these processes of
PARP inhibition on long-term therapeutic responses needs
to be investigated.
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Introduction
While deﬁciencies in DNA repair processes are associated
with cancer susceptibility as has been seen in cancer-prone
syndromes such as Xeroderma pigmentosum, Ataxia
Telangiectasia (AT), Nijmegen Breakage Syndrome
(NBS), and Fanconi’s anemia, the inhibition of DNA repair
and other damage response proteins by small-molecule
inhibitors can potentially be exploited to sensitize tumor
cells when used in combination with chemo- and radio-
therapy or in certain genetic backgrounds. Many therapies,
including alkylating agents such as temozolomide (TMZ),
camptothecins and radiation produce DNA single-strand
breaks (SSBs) and inhibitors of poly(ADP-ribose)poly-
merase (PARP), an essential player in the repair of this
type of DNA damage, have shown great potential as sen-
sitizers in a variety of tumor types. This paper will brieﬂy
review the PARP family and its two most abundant
members, PARP-1 and PARP-2, their role in DNA repair
and other biological processes, and how PARP activity is
being targeted for cancer therapy.
Background: the PARP family
Poly(ADP-ribosyl)ation is a ubiquitous protein modiﬁca-
tion involved in the regulation of transcription, cell
proliferation, differentiation, DNA methylation and apop-
tosis which modulates protein function by regulating either
enzymatic activities or macromolecular interactions
between proteins, DNA or RNA [1–3]. This modiﬁcation is
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syltransferases (ADPRTs) or poly(ADP-ribose) synthetases
a family of abundant eukaryotic enzymes. The family
members are activated in response to different cellular
stresses including transient and localized DNA strand
breaks caused by a variety of biological process such as
DNA repair, recombination, stalled replication forks, gene
rearrangements, as well as by oxidative stress, DNA-
binding drugs and in certain circumstances protein–protein
interactions in the absence of DNA damage. Once acti-
vated, the enzyme rapidly catalyzes the transfer of ADP-
ribose moieties from NAD
? to the acceptor protein
resulting in the attachment of linear or branched polymers
of ADP-ribose (PAR). PARP-1 itself is the primary target
for poly(ADP-ribos)ylation in vivo, with more than 90% of
PAR being found on PARP-1 [4]. The modiﬁcations are
heterogeneous with respect to length (from a few to 200
ADP-ribose units) and extent of branching (one branch per
20–50 ADP-ribose units). A 20 amino-acid PAR-binding
motif was initially established from the analysis of several
DNA-repair and checkpoint proteins [5] and more recently,
using proteomic approaches, a PAR-binding motif was also
identiﬁed in a group of ribonucleoproteins [6]. It was
also shown that the structural macro domain is an ADP-
ribose-binding module [7]. Such domains have been found
in macroH2A, a histone variant involved in transcriptional
repression and chromosome X inactivation [8] and PARP-
9/BAL1, which is over-expressed in diffuse large B-cell
lymphomas [9]. In addition to the direct covalent modiﬁ-
cations of proteins by their PARylation, some proteins have
a high afﬁnity for the polymers themselves and this is
exploited in some settings for the control of their locali-
zation and function [1].
Poly(ADP-ribosyl)ation is a dynamic process consum-
ing substantial amounts of NAD
?. The in vivo half-life of
the polymer is\1 min with the steady-state levels of PAR
being regulated by the catalytic reactions of poly(ADP-
ribose) glycohydrolase (PARG) and possibly the ADP-
ribose hydrolase ARH3. ADP-ribosyl protein lyase, which
cleaves the link between the ﬁrst ADP-ribose and the
modiﬁed amino acids, has been described in rat tissues and
might also function in human cells [10]. The degradation of
PAR may begin immediately after the initiation of PAR
synthesis and can be completed within minutes after the
cessation of PAR synthesis has occurred [4]. This generates
large amounts of AMP that in turn activates the bioener-
getic sensor AMP-activated protein kinase (AMPK).
Based on a structural homology with the catalytic
domain of the PARP-1 protein 17 PARP family members
have been identiﬁed using bioinformatics’ approaches [3].
In addition to the catalytic domain, these proteins typically
contain one or more additional motifs or domains,
including zinc ﬁngers, ‘‘BRCA1 C-terminus-like’’ (BRCT)
motifs, ankyrin repeats, macro domains and WWE
domains (involved in DNA or RNA binding, protein–pro-
tein interaction or cell signaling), conferring unique
properties on each PARP protein [11]. The catalytic
domain of PARP-1 contains three crucial residues: a his-
tidine and a tyrosine that are important for NAD
? binding
and a glutamic acid that is essential for polymerase activity
(discussed in [10]). This latter residue has been replaced in
PARPs 6–16 and raises the question as to whether these
proteins have poly- or mono-(ADP-ribosyl)ating activity.
For instance PARP-10 has transferase rather than poly-
merase activity [12]. A tentative classiﬁcation of PARP-
family members has been proposed according to their
putative functional domains or established functions:
DNA-dependent PARPs (PARP-1 and PARP-2), tanky-
rases, CCCH-type zinc-ﬁnger PARPs, and macroPARPS
[3]. Indeed among the 17 members of the PARP family,
PARP-1 and PARP-2 are the only ones reported until now
to be highly stimulated by DNA damage.
PARP-1
PARP-1, the founding family member, is responsible for
the synthesis of the majority of PAR in eukaryotic cells and
after the histones, is the most abundant nuclear protein
[13]. The gene is located on chromosome 1q41-42 and the
113-kD human PARP-1 (hPARP-1) protein is organized
into at least six domains, four of which have well-deﬁned
functions (Fig. 1). Domain A in the N-terminal region is
the DNA-binding domain (DBD). Its afﬁnity for damaged
DNA is regulated by two zinc-ﬁnger motifs which are
sufﬁcient to target the entire protein to the damaged DNA
[14]. The two PARP-1 zinc-ﬁnger motifs are unique as they
recognize altered DNA structures rather than speciﬁc
sequences: they are known to recognize DNA nicks,
overhangs, blunt ends, and other forms of damage [14–16].
The B domain contains a bipartite nuclear localization
signal (NLS) and a caspase-3 cleavage site. The auto-
modiﬁcation domain D contains a BRCT motif via which
PARP-1 participates in various protein–protein interac-
tions. The domain F is the catalytic C-terminal region [11].
This domain can be reduced to just a 40-kDa C-terminal
polypeptide without losing the basal catalytic activity [17].
Little is known about the function of the C and E domains.
However, a third zinc domain in hPARP-1 has recently
been characterized in the C domain [18, 19]. This region is
thought to modulate the N-terminal-to-C-terminal com-
munication that leads to the DNA-dependent activation of
PARP-1 [18]. Although this zinc ribbon domain does not
bind DNA directly, it is necessary for DNA-stimulated
activation of the full-length enzyme [19]. This has been
recently conﬁrmed by structural analysis of PARP-1
complexed with damaged DNA [20].
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histones, DNA, and other chromatin-associated factors
[21]. Recently, it has been shown that the auto-modiﬁca-
tion of PARP-1 mediates its tight binding to the nuclear
matrix in rat liver cells, creating two PARP-1 pools, and
that this binding is accompanied by increased PARP-1
activity [22].
Expression patterns and genetic variation
PARP-1 and PARP-2 expression and activity have been
assessed in a variety of different cells and tissues. Grube
and Bu ¨rkle [23] compared PARP activities in puriﬁed
leukocytes from 13 mammalian species and found a strong
correlation between activity and lifespan with human cells
displaying approximately ﬁve times the activity of rat cells.
Intra-species comparisons revealed a decline in activity
with age for PARP-1 and PARP-2 but interestingly no
correlation between protein levels and enzymatic activity
(reviewed in [24]). The presence of sequence variants, such
as single nucleotide polymorphism (SNPs), in DNA dam-
age detection and repair genes has been associated with
altered cancer risk and responses to therapy treatment
through the modulation of enzymatic activity in some
cases. Five SNPs with a variant allele frequency[5% have
been reported in the SNP500 study populations within the
coding region of the PARP-1 gene (http://snp500cancer.
nci.nih.gov/snplist.cfm). These include the Val762Ala
variant (c.2285T[C rs1136410) located in exon 17 of the
PARP-1 gene that has been associated with a reduced
enzymatic activity [25–27] and an increased risk of
developing cancers of the prostate, esophageal, lung and
thyroid cancer (reviewed in [24]). A micro satellite poly-
morphism in the promoter, consisting of a variable number
of CAs, has also been identiﬁed [28]. This is located close
to the binding site of the Yin Yang 1 transcription factor
that has been shown to stimulate poly(ADP-ribosy)lation
and DNA repair [29–31]. Zaremba and colleagues [24]
undertook a comprehensive assessment of PARP-1
expression and activity in relation to PARP-1 SNPs in a
panel of 19 solid and hematological adult and pediatric
human cancer cell lines and found a wide range of PARP
activity which was on average higher than the mean
activity measured in normal human lymphocytes from
healthy volunteers and cancer patients, and supports other
observations of increased PARP activity in tumors. For
example, PARP-1 expression is higher in hepatocellular
carcinoma vs. normal liver tissue [32]. However, no cor-
relation was found between PARP activity and PARP-1
protein expression or an association with the status of
either the Val762Ala or the (CA)n polymorphisms.
Dysregulation of PARP-1 gene expression has been found
in a set of 35 breast carcinomas with the majority of breast
tumors strongly expressing PARP-1 mRNA showing an
ampliﬁcation of the 1q41-44 region where PARP-1 is
localized [33]. Clearly, the regulation of PARP-1 activity is
complex and needs further investigations.
PARP-1 and DNA repair
A number of parp-1 knockout mice have been generated
(for instance [34–36]). These animals are viable and fertile,
suggesting that PARP-1 activity is not essential for via-
bility in the absence of genotoxic stress. However, the mice
and derived cells are hypersensitive to ionizing radiation
and alkylating agents, such as MNNG, MNU, or MMS
[37]. Thus although PARP-1 appears to be dispensable for
normal cellular activity, it would appear to be an essential
survival factor for recovery from DNA damage. A second
phenotype observed in these knockout animals is increased
Fig. 1 The domain structure of the two DNA damage-dependent
human PARPs, PARP-1 and PARP-2, showing the DNA-binding, the
automodiﬁcation and catalytic domains (domains A–F). The PARP
signature sequence (in dark blue within the F catalytic domain) is the
most conserved between the PARPs.Z nIand Zn II: Zinc-ﬁnger
motifs. Zn III: Zinc ribbon domain. NLS nuclear localization signal;
BRCT BRCA1 carboxy terminus; NoLS nucleolar localization signal
PARP inhibition and therapy 3651genomic instability. A four- to ﬁvefold increase in the
frequency of sister chromatid exchange has been reported
in the PARP-1 knockout derived cells [38].
In vitro, the ﬁrst role that was described for PARP-1 was
in the response to DNA damage. As discussed above
PARP-1 is a molecular sensor of DNA strand breaks and
through its ribosylating activity plays a key role in the
spatial and temporal organization of their repair. The main
targets for this activity are PARP-1 itself, histones H1 and
H2B, high mobility group proteins (HMGP) (non-histone
components of chromatin), topoisomerases I and II, DNA
helicases, SSB repair (SSBR) and base-excision repair
(BER) proteins and various transcription factors with
proteins either directly interacting with the ADP-ribosy-
lated PARP or via the PARs. Through its own poly(ADP-
ribosyl)ation and that of histones, PARP-1 loosens the
chromatin allowing access to DNA strand breaks and is
also involved in the recruitment of the components of the
BER/SSBR pathways [39]. The automodiﬁcation of PARP-
1 itself promotes its interaction with XRCC1 through its
BRCT domain. This leads to the recruitment of DNA
polymerase b and DNA ligase III thus completing the
repair of the single-strand break. PARP-1 has also
been shown to be involved in human ﬂap endonuclease 1
(FEN-1)-dependent strand displacement during DNA syn-
thesis by DNA polymerase b [40]. In addition to its role in
BER, PARP-1 is involved in several other DNA damage-
repair processes, including the repair of DNA double-
strand breaks (DSBs). For instance, the recruitment of
MRE11, NBS1, and ATM to DSBs has been reported to
depend on PARP-1 activity [41] and PARP-1 is a compo-
nent of an alternative pathway of non-homologous end
joining (NHEJ) [42]. When essential components of the
classical pathway of NHEJ are absent, PARP-1 is recruited
for DSB repair with the ligase III and probably with histone
H1 [43]. The presence of poly(ADP-ribose) chains at the
site of DNA damage also acts as an anti-recombinogenic
factor, preventing the inappropriate recombination of
homologous DNA [44].
PARP-1 and chromatin structure
In the context of the cellular response to DNA damage,
histone modiﬁcations also play an important role in the
recognition and accessibility of sites to the DNA-repair
machinery. Early biochemical studies suggested that
PARP-1 could disrupt chromatin structure by poly(ADP-
ribosyl)ation of histones (mainly histone H1) and destabi-
lization of nucleosomes [45–47]. As mentioned above,
chromatin poly(ADP-ribosyl)ation leads to its deconden-
sation, followed by the release of PARP-1 from the DNA
allowing the recruitment and access of various DNA repair
enzymes [48].
PARP-1 binds to histones H1, H2A, and H2B. In addi-
tion, the core histones H3 and H4 are essential for
PARP-1’s interaction with nucleosomal particles [49].
While histone H4 activates PARP-1 activity, histone H2A
completely inhibits PARP-1 activity [49]. Non-histone
chromosomal proteins, including HMGP and the hetero-
chromatin proteins HP1a and HP1b are also poly(ADP-
ribosyl)ated [50, 51]. In addition to its role in DNA repair,
PARP-1 also plays a role in chromatin repair after oxida-
tive stress. Nucleosomal histones are known to protect
DNA from free radical-mediated damage. This protection
is dependent on nucleosome assembly and does not reﬂect
the presence of scavenging proteins [52]. Oxidatively
damaged histones are able to cross-link with DNA and
would impair the detachment-reassembly process. Thus, to
maintain genomic integrity, the oxidized histones must be
degraded by the 20S proteasome and this degradation is
highly selective following oxidation. While histones H1
and H4 have the highest degradation rates, PARylated
histone H2A is at the other end of the spectrum [53]. The
20S proteasome is known to interact with PARylated
PARP-1 leading to the speciﬁc stimulation of its proteo-
lytic activity [54]. It has been shown recently that
poly(ADP-ribosyl)ation protects histones from degradation
and that oxidized histones are less PARylated, making
them more prone to proteosomal degradation by the acti-
vated proteasome and thus protecting the integrity of the
chromatin [55]. The damage-induced phosphorylation of
histone variant H2AX may serve as a signal for the timely
recruitment and/or retention of DNA repair and check-
points proteins in the vicinity of DNA lesions. The
H2AX-associated factors promote both integration and
dissociation of H2AX and exchange with conventional
H2A histone. These factors include FACT (Spt16/SSRP1),
DNA-PK and PARP-1. It has been shown that FACT,
involved in the H2AX exchange process, is stimulated by
phosphorylation and inhibited by ADP-ribosylation [56].
More recently, the chromatin remodeling enzyme ALC1
(ampliﬁed in liver cancer 1), a member of the SNF2
superfamily of ATPases, has been shown to be rapidly
recruited to DNA damage sites via an interaction with
poly(ADP)ribosylated PARP-1, activating its ATPase and
chromatin remodeling activities and catalyzing PARP1-
stimulated nucleosome sliding [57, 58].
The combined effects of (ADP-ribosyl)ation and other
post-translational modiﬁcations have also been described.
For instance (ADP-ribosyl)ation can occur on acetylated
core histones and newly synthesized core histones can be
reversibly acetylated and (ADP-ribosyl)ated, probably to
facilitate their assembly into histone complexes and
accessibility during replication [59].
PARP-1 and PARG have also been shown to inﬂuence
chromatin domain structure through their interaction with
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?-dependent histone-deacetylase silent informa-
tion repressor protein-2 (SIR2) resulting in the silencing of
speciﬁc chromosomal domains in drosophila [60]. The
molecular dissection of these interactions is facilitated in
this model system that only has a single Parp gene which
encodes a protein with the same domain structure as
PARP-1, a single tankyrase gene and a single gene pre-
dicted to encode a PARG protein and in which Parp
mutations are lethal and drastically alter many aspects of
developmental physiology [61]. The activation and ADP-
ribosylation of PARP (and possibly other local chromatin
proteins) loosens chromatin structure early in the silencing
process and this facilitates SIR2 access to acetylated his-
tone tails. PARG contributes to this process by degrading
protein bound ADP-ribose moieties, and thus controlling
SIR2 activity and localization [60].
Another dimension to the regulatory functions of PARP-
1 is its role in the regulation of DNA methylation patterns,
gene silencing, and imprinting (reviewed by [62]). CTCF, a
nuclear factor involved in imprinting and insulator pro-
cesses, activates PARP-1 activity inducing PARP-1 auto-
modiﬁcation. These polymers non-covalently interact with
the DNA methyl-transferase 1 (Dnmt1), inhibiting its
enzymatic activity. In the absence of PARylated PARP-1,
the Dnmt1 is free to methylate DNA, whereas if the levels
of PARylated PARP-1 remain high (for instance if PARG is
absent), the stable inhibition of Dnmt1 would prevent DNA
methylation resulting in DNA hypomethylation. It would
seem that not only can PARylated PARP-1 bind Dnmt1 but
it can also bind to the Dnmt1 promoter, maintaining this
region unmethylated [63]. Thus the deregulation of PAR
levels, which is dependent on the balance between PARP
and PARG activities, could have a major impact on cellular
methylation patterns.
Other cellular functions of PARP-1
As discussed above, PARP-1 can inﬂuence transcription
and gene expression via several non-exclusive mechanisms
including its histone-modifying enzymatic activity
promoting the dissociation of nucleosomes and the
decondensation of chromatin and regulating genome
methylation patterns. In addition, PARP-1 can act through
its direct interaction with transcription factors and their
binding sites. PARP-1 has been shown to function as a
transcriptional co-activator of NF-jB, the transcription
factor that regulates immune and inﬂammatory response
genes [64].
The discovery that PARP-1 can also be activated by
certain types of DNA structures, such as hairpins, cruci-
forms, and supercoiled DNA [15], invalidated the dogma
that DNA beaks are essential for its activation. Protein–
protein interactions in the absence of DNA in vivo and in
vitro, as reported for phosphorylated ERK2 [65] and for the
CCCTC-binding factor [66], have also been shown to result
in PARP-1 activation. The elucidation of the mechanism
that leads to this activation remains to be established.
PARP-2
Cells derived from parp-1 knockout mice were shown to be
capable of synthesizing poly(ADP-ribose) in response to
DNA damage [67]. Such studies led to the discovery of a
second DNA-damage-activated PARP, PARP-2, that is
also a nuclear protein and forms PAR in response to DNA
damage. The activity of PARP-2 accounts for approxi-
mately 10% of the total PARP activity of human cells [68].
Mice in which the parp-2 gene is deleted are viable,
however if both parp-1 and parp-2 are deleted embryonic
lethality is observed, suggesting that there is some overlap
in their functional activities [69]. Although Parp-2
knockout mice are generally less sensitive to DNA damage
produced by IR than parp-1 knockout mice [69], parp-2
knockout cells are more sensitive to doses below 2 Gy,
raising the possibility that PARP-2 plays a role in the G2/M
phase cell-cycle checkpoint activated in response to low
doses of ionizing radiation [70].
Among the PARP family members, PARP-2 is the
closest relative of PARP-1 with their catalytic F-domains
having approximately 69% similarity. The N-terminal
domain of murine PARP-2 does not contain zinc-ﬁnger
motifs but a highly basic DBD, a NLS and a nucleolar
localization signal (NoLS; Fig. 1) which displays homol-
ogy with the SAP domain found in various nuclear proteins
like APE-1 and Ku-70, involved in chromosomal organi-
zation or DNA repair. The PARP-2 DBD is structurally
different from that of PARP-1, probably reﬂecting differ-
ences in the DNA structures recognized by each enzyme
[11, 68]. The PARP-2 E domain acts both as the interacting
interface with various partners and as an auto-modiﬁcation
domain [71]. The border between the E and F domains
contains a caspase-8 cleavage site [72].
PARP-1 and PARP-2 can homo-and hetero-dimerize
and poly(ADP-ribose)ate each other [71]. PARP-2 was
found to interact with the BER proteins XRCC1, DNA
polymerase b and DNA ligase III, all of which are PARP-1
partners [71]. PARP-2 is a component of a functional BER
complex in vivo, however, PARP-1 and PARP-2 were
shown to accumulate with different kinetics at laser-
induced DNA damaged sites, leading to an implication of
PARP-2 at later steps in the BER/SSB repair process [73].
PARP-2 was recently shown to be critical for PARP-1
mediated activation of homologous recombination at stal-
led replication forks [74]. Some other speciﬁc functions
have been shown for PARP-2, for instance a role in gen-
ome surveillance, the maintenance of telomere integrity,
PARP inhibition and therapy 3653translocations during immunoglobulin class switch
recombination, spermatogenesis, adipogenesis and T cell
development, and the maintenance of centromeric hetero-
chromatin integrity (reviewed in [72]). PARP-2 has been
proposed to play a role in the G2/M phase cell-cycle
checkpoint in response to low-dose ionizing radiation,
pointing to possible clinical applications of speciﬁc PARP-2
inhibitors in combination with continuous low-dose
radiotherapy [72].
The cellular consequences of PARP inhibition
PARP inhibitors and chemopotentiation
One of the ﬁrst reports that a PARP inhibitor enhanced
cytoxicity came 30 years ago from the group of Sydney
Shall [75] who demonstrated that 3-aminobenzamide
(3-AB) prevented the rejoining of DNA strand breaks
caused by the alkylating agent dimethyl sulphate and
increased its toxicity in L1210 mouse leukemia lympho-
blast cells. 3-AB is a simple analogue of nicotinamide, the
other product of PARP-1 mediated catalysis of NAD
?,
itself a weak PARP inhibitor. Most inhibitors act through
binding to the catalytic domain of the enzyme and thus
while are speciﬁc for PARP activity, are not selective for
the different members of the PARP superfamily. The
benzamides are approximately 10–20 fold more potent than
nicotinamide but lack the speciﬁcity and potency to be
of use in preclinical and clinical studies. These observations
lead several groups to embark on PARP inhibitor devel-
opment programs. For instance, Banasik and colleagues
[76] identiﬁed a number of more potent inhibitors including
1,5-dihydroisoquinoline, 2-methyquinazolin-4-(3H)-one,
4-amino-1-8-napthalimide and 2-nitro-6-(5H)-phenanth-
ridinone, which have been used as lead compounds for
subsequent drug development and the identiﬁcation of the
essential features for efﬁcient PARP inhibition through
structure–activity studies (see [77]). Inhibitor design has
also been aided by crystallographic studies of inhibitors
bound to PARP catalytic sites, such as those recently
published for the catalytic domain of human PARP-2 in
complex with the PARP inhibitor ABT-888 [78]. The
results contribute to the understanding of the structural
similarities and differences that can be exploited to design
more selective inhibitors but for most cross-reactivity
between different members of the human PARP family is
observed. These proteins share only between 18 and 45%
homology in their catalytic domains, but crystal structures
indicate their structure is conserved and the mode of NAD
?
cofactor binding is very similar.
Using this rational drug design approach, more potent
inhibitors have been identiﬁed and that had low toxicity
and were active in combination studies with anticancer
chemotherapies in xenograft models (see [79]). For
instance, Miknyocksli et al. [80] showed that CEP-6800, a
3-amonomethyl carbazole imide inhibitor of PARP-1 and
PARP-2, potentiated the antitumor activity of TMZ,
irinotecan, and cisplatin against tumor xenografts in
mouse, Tentori et al. [81] that GP1 15427 could enhance
the antitumor efﬁcacy of TMZ against melanoma, glio-
blastoma multiforme, and lymphoma growing in the mouse
brain, and Calabrese and colleagues found an improved
therapeutic index with AG14361, an inhibitor 1,000 times
more potent than 3-AB, in combination with TMZ, irino-
tecan, and radiation in a human colon tumor xenograft
model [82]. The monofunctional alkylating agent TMZ
generates three major modiﬁed bases in DNA, N7-meth-
ylguanine, 3-methyladenine and O
6-methylguanine, the
latter being repaired by the O
6-methylguanine-DNA
methyltransferase (AGT). If not repaired by AGT, the
mismatch repair (MMR) pathway intervenes, but as the
modiﬁed base is located in the template strand, this triggers
repeated cycles of MMR-mediated excision/resynthesis,
which eventually leads to the generation of single-stand
breaks, growth arrest, and apoptosis. The enhancement of
the antitumor activity of TMZ by the presence of a PARP
inhibitor comes from the blocking of BER that removes the
N-methylpurines (reviewed in [79]). However, recent data
from Horton et al. [83] has shown that potentiation can be
found in a variety of repair backgrounds in leukemia cells.
They found that while the inhibitor ABT-888 enhanced
TMZ growth inhibition most effectively in MMR-deﬁcient
cells with low MGMT activity, it also potentiated TMZ
activity in MMR-deﬁcient cells with elevated MGMT
activity and unexpectedly in MMR-proﬁcient leukemia
cells. Clearly the mechanistic basis of these observations
needs further investigation but they do suggest that the
potentiation might be independent of MGMT status open-
ing up the possibility of using this drug combination in
other clinical settings.
The ﬁrst phase 1 clinical trial of a PARP inhibitor was
carried out between 2003 and 2005 with AGO14699, a
potent tricyclic indole inhibitor, in combination with TMZ
in patients with advanced solid tumors [84] and paved the
way for other trials with other PARP inhibitors in combi-
nation with chemotherapeutic agents (www.clinicaltrials.
gov; recently reviewed in [10] and [85]). A total of 48
clinical trials involving PARP inhibitors in a cancer setting
are registered: 24 phase I, 2 phase I/II, 2I phase II and one
phase III study involving over 4,500 patients. The majority
of these trials will combine a PARP inhibitor with standard
chemotherapeutic protocols, for instance with TMZ in
patients with skin and solid tumors, with the largest being a
phase III trial of gemcitabine/carboplatin with or without
the PARP inhibitor BS1-201 in patients with previously
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ECLIPSE trial, which has a start date of March 2010. The
remaining trials are either combining PARP inhibitors
with radiation or are targeting tumors, which as discussed
below, are genetically predisposed to die when PARP
activity is inactivated or share characteristics of such
tumors.
PARP inhibitors and radiosensitization
Early experimental evidence had also shown that PARP
inhibitors acted as radiosensitizers in rodent cells, but their
effect against human cells was often only marginal ([86]
and refs therein). To elucidate the origin of this apparent
differential radiosensitization, our group assessed the
radiation survival of a panel of human and rodent cell lines
including PARP-1 repair-deﬁcient and repair-proﬁcient
mouse 3T3 ﬁbroblasts cell lines, in the absence and pres-
ence of the PARP inhibitor 4-amino-1,8-naphthalimide
(ANI). The results suggested that radiosensitization by ANI
depends primarily on the percentage of cells engaged in
DNA replication. Indeed, in synchronized HeLa cells,
radiosensitization by ANI was found to occur speciﬁcally
in the S phase of the cell cycle [86].
The consequences of PARP-1 disruption or inhibition
on DNA SSBR and radio-induced lethality were further
investigated in synchronized, isogenic HeLa cells stably
silenced or not for PARP-1 (PARP-1-KD) or XRCC1
(XRCC1-KD) [87]. PARP inhibition prevented the
recruitment of XRCC1 at sites of 405 nm laser micro
irradiation, slowed SSBR tenfold and triggered the accu-
mulation of large persistent foci of PARP-1 and PCNA at
photo-damaged sites which we believe hinder the recruit-
ment of other effectors of the BER pathway. Under these
experimental conditions where PARP was inhibited, radi-
osensitization occurs only in those cells treated in S phase
(Fig. 2) due to the collision of the persisting SSBs with
replication forks and the formation of a lethal DNA double
strand breaks. The inhibitor used in this study, as in many,
targets both PARP-1 and PARP-2 activity and thus for-
mally a role of PARP-2 in this radiosensitization can not be
ruled out. The development of inhibitors with a greater
speciﬁcity for PARP-2 compared to PARP-1 and cell line
models lacking just PARP-2 will allow us to address its
relative contribution to this response.
PARP-1 silencing also prevented XRCC1 recruitment to
damage sites but did not lengthen the lifetime of PCNA foci
and we found that PARP-1-KD and XRCC1-KD cells in S
phase completed SSBR as measured by alkaline elution as
rapidly as in controls, while SSBR was delayed in G1.
Taken together, the data demonstrate that a PARP-1 and
XRCC1-independent SSBR pathway operates when the
short patch repair (SPR) branch of BER is absent. The likely
mechanism is a switch from SPR to long patchrepairbranch
as PCNA recruitment at photo-damaged sites was normal in
PARP-1-KD cells (Fig. 2). PARP-1 silencing, however,
under these conditions elicited hyper-radiosensitivity,
which is not seen in cells in which XRCC1 is depleted
(Fig. 3). As SSBR is completed in both cell types, it would
suggest that some other activity of PARP-1, other than its
role in SSBR, is the underlying cause of this radiation
sensitivity. As discussed above, PARP-1 plays a role in the
condensation of chromatin and transcriptional repression
and our working model is that altered regulation of chro-
matin conformation following suppression of PARP-1
results in enhanced susceptibility to radiation-induced
damage. However, it can not be excluded that PARP-1 plays
a role in the processing of DSBs. Studies from our group
had shown that the incidence and the rejoining kinetics of
neocarzinostatin-induced DNA double-strand breaks was
identical in PARP-1
?/? and PARP-1
-/- 3T3 cells. This
would suggest that PARP-1 is not a major determinant of
DNA double-strand break recovery with either strand break
rejoining or cell survival as an endpoint [88]. However,
recent studies that investigated the activation of PARP-1
Fig. 2 Scheme summarizing the differential effect of PARP-1
inhibition versus silencing on SSB repair via the BER pathway.
The experimental evidence would suggest that SSB rejoining
proceeds via the LPR sub-pathway when the SPR is deﬁcient because
of a lack of PARP-1. In contrast, inhibition of poly(ADP-ribosyl)ation
in PARP-1-proﬁcient cells was found to result in the accumulation of
PARP-1 and PCNA in the vicinity of DNA damaged sites, with a
tenfold reduction of the bulk rate of SSBR. This does not impact on
radiosensitivity in the G1 phase of the cell cycle, probably because
cells have enough time to perform SSB repair. However, under such
conditions in S phase collision of unrepaired SSBs with replication
forks results in a increase of radiosensitivity due to the formation of a
large number of DSBs (reproduced with permission from [87])
PARP inhibition and therapy 3655and DNA-dependent protein kinase (DNA-PK), a key
player in DSB repair, by different types of DNA ends and
the interaction of these two proteins in the cellular response
to ionizing radiation do suggest that PARP-1 is required for
a pathway that facilitates the fast repair of DNA DSBs [89].
Making use of the PARP inhibitor (KU-0058684) and the
DNA-PK inhibitor (NU7441) Mitchell and colleagues,
found that the inactivation of the two proteins was not
additive, suggesting that they co-operate within the same
pathway and that they showed similar and overlapping
afﬁnities for oligonucleotides with blunt, 30GGG or 50GGG
overhanging termini. The exact molecular mechanisms of
this interaction clearly remain to be established. One pos-
sible link between PARP-1 and DNA-PK is the cyclin-
dependent kinase 5 (CDK5). Identiﬁed in a synthetic lethal
siRNA screen for genes that mediate sensitivity to PARP
inhibitors [90], CDK5 is a proline-directed serine/threonine
kinase activated by the non-cyclin proteins p35 and p39. It
is a very abundant protein in the nervous system and has
been implicated in neurodegeneration and neurodegenera-
tive diseases where it is believed to play a role in the
changes in cell-cycle regulation which precede neuron
death (for review see [91]). The underlying mechanisms
have been suggested to involve the inhibition of chromatin
condensation as well as modulation of the activity of the
DNA DSB repair protein ataxia-telangiectasia mutated
(ATM) that was found to be phosphorylated by CDK5 in the
nucleus of neuronal cells following exposure to campto-
thecin [92]. O’Hare and colleagues [93] showed a reduction
in nuclear p35, a CDK5 cofactor, and an increase in nuclear
CDK5 with increasing time of exposure to camptothecin in
primary neuronal cultures suggesting that its relocation is
important in the damage responses and the inhibition of
CDK5 activity has also been shown to increase DNA
damage-induced neuronal death [94].
Turner and colleagues showed that CDK5 functions in
the DNA damage response in human breast cancer cells. In
these cells, CDK5 silencing induced spontaneous formation
of DNA DSBs and an increased sensitivity to camptothecin
[90]. Additionally, an increase in endogenous CDK5
activity after irradiation was observed in this cell type. They
hypothesized that the mechanism of sensitivity to PARP
inhibitor is a failure of the G2/M cell-cycle checkpoint. It is
possible that in the presence of greatly increased level of
SSBs, failure of this checkpoint leads to replication fork
collapse and subsequent cell death. Interestingly, both ATM
and PARP-1 have been shown to be phosphorylated by
CDK5 together with other factors implicated in chromatin
modiﬁcations [95]. Therefore, based on these observations
an alternative hypothesis for the increased radiation sensi-
tivity seen in the absence of PARP-1 is via a link with
CDK5 and through it a modulation of DSB repair and
activation of cell-cycle checkpoints.
The implication of these results is that both the absence
of PARP-1 and the inhibition of PARP activity will
enhance the cytoxicity of radiotherapy particularly in rap-
idly dividing tumors and this working hypothesis has been
supported by results from a number of groups using dif-
ferent PARP inhibitors and experimental models. Chalmers
and colleagues showed that the PARP-1 and PARP-2
inhibitor KU-0059436/AZD2281/olaprib increases the
radiosensitivity of human glioma cell lines by a replication-
dependent mechanism that generates persistent DSBs [96].
They have since shown that the simultaneous inhibition of
homologous recombination further enhances the radiosen-
sitizing effect of PARP inhibitors in replicating human
glioma cells. The inhibition of the chaperone protein heat
shock protein 90 results in the downregulation of BRCA2
and Rad51 protein levels and additive radiosensitization
was observed [97]. Whether the radiation sensitivity
observed when a PARP inhibitor is combined with radia-
tion is exclusively due to compromised SSBR that results
in an increase in DSBs or whether DSB repair is also
modulated remains to be fully established. The PARP
inhibitor E7016 (formerly known as GPI21016) has also
been shown to enhance tumor cell radiosensitivity in vitro
and in vivo and enhanced growth delay seen with the
addition of E7016 to temozolomide and radiotherapy in a
glioma mouse model suggests a potential role for this drug
combination in the treatment of glioblastoma multiforme
[98]. Preclinical data showing an enhancement of the
response of tumor cells to radiation has now been
Fig. 3 Radiation survival in control, PARP-1-KD, and XRCC1-KD
HeLa cells synchronized in S phase. Cells were synchronized by a
double thymidine block, allowed to progress in S phase for 2 h and
exposed to increasing doses of gamma rays. Following treatment, the
cells were allowed to grow as colonies for 10–15 days, ﬁxed, stained
with Coomassie Blue, and then counted. The experimental data for
control and XRCC1-KD lay within the same envelope of statistical
deviation whereas the PARP-1-KD cells showed an enhanced
radiation sensitivity (reproduced with permission from [87])
3656 F. Me ´gnin-Chanet et al.documented for several PARP inhibitors including
AG14361 [82], ABT-888 [99, 100], INO-1001 [101], and
radiosensitization of human and rodent cell lines by INO-
1001 and GPI15427 (MGI Pharma) [102] has been repor-
ted. These preclinical studies have lead to date to the start
of three phase I clinical trials which will evaluate the safety
of PARP inhibitors in addition to radiotherapy. One will
test ABT-888 in combination with whole-brain radiation
therapy in subjects with brain metastases. The two others
will test either ABT-888 or BSI-201 in combination with
TMZ and radiation therapy in subjects with newly diag-
nosed glioblastoma.
PARP inhibitors as single therapeutic agents
In 2005, the groups of Ashworth and Helleday [103, 104]
showed preclinically that BRCA1 and BRCA2-deﬁcient
cells, in which the homologous recombination DSB repair
pathway was compromised, were hypersensitive to the
blockade of SSB repair by inhibition of PARP activity and
demonstrated for the ﬁrst time the potential use of PARP
inhibitors as single therapeutic agents. The mechanistic
basis of this cytoxicity is that blocking SSB repair leads to
the formation of DSBs at the replication forks. In normal or
heterozygote cells, the intact DSB repair can process these
lethal lesions, but DSB repair is compromised in tumor cells
that have lost the remaining BRCA1 or BRCA2 wild-type
allele. The loss of both SSB and DSB repair pathways
causes cell death. This is an example of the concept of
synthetic lethality, deﬁned as the situation when mutation in
either of two genes individually has no effect but combining
the mutations leads to death, that is proving to be a prom-
ising approach in the development of cancer treatments.
A number of clinical trials have been initiated to test the
efﬁcacy of this approach. The orally active PARP inhibitor
olaparib (previously known as KU0059436) was tested in a
phase 1 trial in a study population of 60 patients that was
enriched for carriers of a BRCA1 or BRCA2 mutation
[105]. The trial showed that olaparib had an acceptable
side-effect proﬁle and did not have the toxic effects
commonly associated with conventional chemotherapy.
Pharmacokinetic data indicated rapid absorption and
elimination and pharmacodynamic studies conﬁrmed
PARP inhibition in surrogate samples and tumor tissues
and a clinical beneﬁt was observed but only in mutation
carriers. Over 650 individuals will be included in the reg-
istered phase I and II trials of PARP inhibitors as a single
agent for the treatment of breast, ovarian, prostate and
pancreatic cancers in BRCA1 and BRCA2 mutation carri-
ers, which are underway or in the planning stages (www.
clinicaltrials.gov; recently reviewed by [106]).
Effective HR requires many proteins and this opens the
possibility that synthetic lethality can be achieved in
pathological settings where other components of the HR
pathway are lacking through germline and/or somatic
mutations or via other mechanisms that control protein
expression in combination with PARP inhibitors. For
example, recent results from Mendes-Pereira et al. [107]
have shown that cells harboring PTEN mutations are sen-
sitive to PARP inhibitors. Similarly, ATM deﬁciency,
which is often found in mantle cell lymphoma, confers
sensitivity to PARP inhibitors [108].
PARP inhibitors in other clinical settings
As discussed [109], PARP-1 functions as a double-edged
sword: on the one hand, activation of PARP is essential for
DNA repair, but on the other hand, over-activation repre-
sents an important mechanism of tissue damage in various
pathological conditions associated with oxidative and
nitrosative stress, including myocardial reperfusion injury,
heart transplantation, and autoimmune B-cell destruction
associated with diabetes mellitus and hepatic injury. Con-
tinuous or excessive activation of PARP produces a
depletion of NAD
? and ATP, slowing glycolysis and
mitochondrial respiration, which could eventually lead to
cellular dysfunction and necrotic cell death. PARP acti-
vation also has consequences on the transcriptional
regulation of several proteins including other transcrip-
tional factors, such as NF-jB, implicated in inﬂammation.
The beneﬁcial effects of the inhibition of PARP have been
demonstrated in a number of cardiovascular situations and
there is considerable expectation that the use of PARP
inhibitors will be an efﬁcient therapy (see recent reviews
by [109–112]).
Recently, Quiles-Perez et al. [32] have shown that
PARP inhibition is capable of controlling hepatocellular
carcinoma xenograft growth, protected against diethylni-
trosamine-induced hepato-carcinogenesis and prevented
tumor vasculogenesis by transcriptional regulation of both
transcription factors and the expression of genes involved
in tumor progression. These changes in the tumor micro-
environment brought about by PARP inhibition can also
have an impact on responses to radiotherapy and drug
delivery. Vasoactivity has been reported for the PARP
inhibitors AG14361 [82] and AG0014699 (Pﬁzer Oncol-
ogy) [113] and differences were noted between the
chemopotentiating effect of AG0014699 in vitro and in
vivo models: the sensitivity of SW620 cells to TMZ was
not enhanced by AG0014699 in vitro but in vivo the
combination of AG0014699 and TMZ gave rise to pro-
nounced tumor growth delays at doses of TMZ that alone
gave only transient delays. Another tumor microenviron-
ment that inﬂuences the chemo- and radioresistance of
tumors is hypoxia. Hypoxic cells are 2.5 to threefold more
radioresistant than oxic cells and intra-tumoral hypoxia can
PARP inhibition and therapy 3657be a signiﬁcant cause of treatment failure after radical
radiotherapy. The group of Bristow [114] hypothesized that
PARP inhibition may be useful in radiosensitizing hypoxic
tumor cells, which they demonstrated using in vitro models
and the inhibitor ABT-888, making these agents attractive
adjuncts for radiotherapy via mechanisms other than the
inhibition of DNA repair.
Conclusions
There is a growing body of literature and editorials docu-
menting and discussing the impact of PARP inhibitors as
effective chemo- and radiopotentiation agents and, in
BRCA-deﬁcient tumors, as single-agent therapies. Clearly,
their potential has caught the attention of researchers and
industrialists, but there are many aspects of their use that
still need to be established. For instance, PARP inhibitor-
chemotherapy drug combinations for different tumor types
remain to be fully optimized, as does the dose and schedule
to maximize efﬁcacy while minimizing side-effects. The
same considerations apply to using PARP inhibitors to
potentiate the effects of radiotherapy, where the complex
interaction of dose and schedule may also inﬂuence the risk
of developing adverse secondary reactions such as radia-
tion-induced ﬁbrosis and secondary cancers. Emerging
evidence suggests that many sporadic tumors display a
certain degree of ‘‘BRCAness’’ [115], that is they share
expression proﬁles that are found in tumors from BRCA1
and BRCA2 mutation carriers. The phenotypic similarities
between some ‘‘triple-negative’’ breast cancers and the
most prevalent type of breast cancer seen in BRCA1
mutation carriers has lead to suggestions that these difﬁ-
cult-to-treat breast tumors would be sensitive to PARP
inhibition (recently reviewed in [116]). Indeed there are
ﬁve registered clinical trails in which this will be assessed
and preliminary results from a phase II trial presented at
ASCO and reported in JNCI [117] are very encouraging.
The challenge remains to identify those subgroups of
patients who could beneﬁt from single-agent PARP
inhibition.
The development of resistance to targeted therapy must
also be considered. PARP-inhibitor-resistant clones have
been derived from the human BRCA2-deﬁcient cell line
CAPAN1 by a deletion of a mutation in BRCA2 [118]. A
similar mechanism seems to be associated with carboplatin
resistance in some BRCA2 mutation carriers with ovarian
cancer (reviewed in [119]). Whether all mutations will
revert at the same frequency remains to be established, but
this eventuality has to be taken into consideration when
determining treatment options. Over the last decade, cer-
tain biological functions and the mode of action of some of
the PARP family members have been deciphered, however,
it has become increasingly clear that family members
participate in a wide range of cellular processes. For
instance, PARP-1 not only plays a role in DNA repair but is
an important transcriptional activator, and in particular of
the NF-jB stress-inducible transcription factors. What the
long-term effects are on cellular homeostasis, including the
epigenetic control of gene expression, of the inhibition of
PARP activity and deciphering how this might impact
long-term therapeutic responses will be a challenge for the
next decade.
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